Want to see IN:AKUMS full AI Analyst Report?
AKUMS Stock Chart & Stats
₹684.40
-₹11.70(-1.70%)
At close: 4:00 PM EDT
₹684.40
-₹11.70(-1.70%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹796.20
Previous CloseN/A
Volume178.53K
Average Volume (3M)16.32K
Market Cap
₹122.26B
Enterprise Value₹56.30K
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)40.9
Beta1.13
Next Earnings
Nov 09, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume17,194
30 Day Avg. Volume16,317
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)26.73
Revenue Forecast (FY)₹49.50B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Earnings TurnaroundSustained revenue expansion and a return to profitability indicate improving operating scale and customer demand. As a CDMO serving multiple therapeutic areas and markets, this recovery can support durable growth if repeat client orders continue.
Strengthened Balance SheetVery low leverage and a materially larger equity base improve financial resilience and reduce dependence on debt funding. This gives Akums greater flexibility to sustain operations and invest in manufacturing capacity through business cycles.
Improved Cash GenerationStrong operating and free cash flow provide internal funding for capital expenditure, working capital and debt needs. Improved cash conversion also makes the earnings recovery more financially credible, provided recent generation is maintained.
Bears Say
Sharp Margin CompressionThe steep FY26 margin decline signals pressure from costs, product mix or one-off items. If persistent, weaker per-unit economics could limit earnings growth even as revenue expands and reduce the benefit of Akums’ manufacturing scale.
Earnings Growth Remains WeakNegative EPS growth indicates that the recent revenue and profit recovery has not translated into consistent per-share earnings improvement. Continued dilution, margin pressure or operating volatility could constrain shareholder returns over the medium term.
Historically Volatile Cash ConversionRecent cash generation is encouraging, but the historical pattern suggests working-capital or investment demands can materially disrupt conversion. This creates uncertainty around the durability of free cash flow and the reliability of internally funded growth.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹796.20 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹122.26B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Nov 09, 2026 which is in 68 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on Aug 08, 2026. The company reported ₹6.4 earnings per share for the quarter, beating the consensus estimate of ₹6.1 by ₹0.3.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.38%. See more information on Akums Drugs and Pharmaceuticals Limited dividends here
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹6.4 in its last earnings report, beating expectations of ₹6.1. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).
Technical Analysis
Glenmark Life Sciences Limited
―
Jubilant Pharmova Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Sudeep Pharma Limited
―